MARKETABLE SECURITIES (Details Narrative) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Dec. 31, 2017 |
|
| Restructuring Cost and Reserve [Line Items] | |||
| Marketable Securities, Unrealized Gain (Loss) | $ 7,300 | $ 100 | |
| Marketable Securities | $ 3,700 | $ 11,000 | |
| Amarantus BioScience Holdings, Inc. [Member] | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Stock Issued During Period, Shares, Acquisitions | 1,000,000 | ||
| Stock Issued During Period, Value, Acquisitions | $ 40,980 | ||
| X | ||||||||||
- Definition Amount of investment in marketable security. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment in marketable security. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Number of shares of stock issued during the period pursuant to acquisitions. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Value of stock issued pursuant to acquisitions during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|